Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 38

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor

Mikulak, Joanna, Bozzo, Luisa, Roberto, Alessandra, Pontarini, Elena, Tentorio, Paolo, Hudspeth, Kelly, Lugli, Enrico, Mavilio, Domenico·2014·The Journal of Immunology

Abstract

Several lines of evidence indicate that dopamine (DA) plays a key role in the cross-talk between the nervous and immune systems. In this study, we disclose a novel immune-regulatory role for DA: inhibition of effector functions of activated NK lymphocytes via the selective upregulation of the D5 dopaminergic receptor in response to prolonged cell stimulation with rIL-2. Indeed, engagement of this D1-like inhibitory receptor following binding with DA suppresses NK cell proliferation and synthesis of IFN-γ. The inhibition of IFN-γ production occurs through blocking the repressor activity of the p50/c-REL dimer of the NF-κB complex. Indeed, the stimulation of the D5 receptor on rIL-2–activated NK cells inhibits the binding of p50 to the microRNA 29a promoter, thus inducing a de novo synthesis of this miRNA. In turn, the increased levels of microRNA 29a were inversely correlated with the ability of NK cells to produce IFN-γ. Taken together, our findings demonstrated that DA switches off activated NK cells, thus representing a checkpoint exerted by the nervous system to control the reactivity of these innate immune effectors in response to activation stimuli and to avoid the establishment of chronic and pathologic inflammatory processes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1401114

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 68

  1. Qiu, 1996, Immunoregulatory role of neurotransmitters, Adv. Neuroimmunol., 6, 223, 10.1016/S0960-5428(96)00018-6 · DOI
  2. Weigent, 1987, Interactions between the neuroendocrine and immune systems: common hormones and receptors, Immunol. Rev., 100, 79, 10.1111/j.1600-065X.1987.tb00528.x · DOI · Paper page
  3. Bencsics, 1997, Dopamine, as well as norepinephrine, is a link between noradrenergic nerve terminals and splenocytes, Brain Res., 761, 236, 10.1016/S0006-8993(97)00313-2 · DOI
  4. Haskó, 1998, Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system, Biochem. Pharmacol., 56, 1079, 10.1016/S0006-2952(98)00153-1 · DOI · Paper page
  5. Mignini, 2003, Autonomic innervation of immune organs and neuroimmune modulation, Auton. Autacoid Pharmacol., 23, 1, 10.1046/j.1474-8673.2003.00280.x · DOI · Paper page
  6. Ferrari, 2004, Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes, Biochem. Pharmacol., 67, 865, 10.1016/j.bcp.2003.10.004 · DOI
  7. Kirillova, 2008, Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays, J. Neurosci. Methods, 174, 272, 10.1016/j.jneumeth.2008.07.018 · DOI
  8. McKenna, 2002, Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study, J. Neuroimmunol., 132, 34, 10.1016/S0165-5728(02)00280-1 · DOI · Paper page
  9. Nakano, 2008, Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis, Biochem. Biophys. Res. Commun., 373, 286, 10.1016/j.bbrc.2008.06.012 · DOI
  10. Nakano, 2009, Dopamine released by dendritic cells polarizes Th2 differentiation, Int. Immunol., 21, 645, 10.1093/intimm/dxp033 · DOI
  11. Besser, 2005, Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both, J. Neuroimmunol., 169, 161, 10.1016/j.jneuroim.2005.07.013 · DOI · Paper page
  12. Ghosh, 2003, Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells, Int. Immunopharmacol., 3, 1019, 10.1016/S1567-5769(03)00100-0 · DOI
  13. Levite, 2001, Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function, Eur. J. Immunol., 31, 3504, 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F · DOI
  14. Sarkar, 2006, Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation, J. Immunol., 177, 7525, 10.4049/jimmunol.177.11.7525 · DOI
  15. Watanabe, 2006, Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3, J. Immunol., 176, 848, 10.4049/jimmunol.176.2.848 · DOI · Paper page
  16. Pacheco, 2009, Role of dopamine in the physiology of T-cells and dendritic cells, J. Neuroimmunol., 216, 8, 10.1016/j.jneuroim.2009.07.018 · DOI
  17. Sarkar, 2010, The immunoregulatory role of dopamine: an update, Brain Behav. Immun., 24, 525, 10.1016/j.bbi.2009.10.015 · DOI · Paper page
  18. Lachowicz, 1997, Molecular characteristics of mammalian dopamine receptors, Pharmacol. Toxicol., 81, 105, 10.1111/j.1600-0773.1997.tb00039.x · DOI
  19. Missale, 1998, Dopamine receptors: from structure to function, Physiol. Rev., 78, 189, 10.1152/physrev.1998.78.1.189 · DOI · Paper page
  20. Neve, 2004, Dopamine receptor signaling, J. Recept. Signal Transduct. Res., 24, 165, 10.1081/RRS-200029981 · doi:10.1081/rrs-200029981 · Paper page
  21. Cosentino, 2007, Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop, Blood, 109, 632, 10.1182/blood-2006-01-028423 · DOI · Paper page
  22. Saha, 2001, Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism, Neuroimmunomodulation, 9, 23, 10.1159/000049004 · DOI
  23. Chang, 2000, Catecholamines inhibit microglial nitric oxide production, Brain Res. Bull., 52, 525, 10.1016/S0361-9230(00)00291-4 · DOI
  24. Brunetta, 2010, Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes, J. Leukoc. Biol., 88, 1119, 10.1189/jlb.0410225 · DOI
  25. Teunis, 2004, Reduced splenic natural killer cell activity in rats with a hyperreactive dopaminergic system, Psychoneuroendocrinology, 29, 1058, 10.1016/j.psyneuen.2003.09.007 · DOI
  26. Kavelaars, 2005, Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene, J. Neuroimmunol., 161, 162, 10.1016/j.jneuroim.2005.01.004 · DOI
  27. Zhao, 2013, Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway, PLoS ONE, 8, e65860, 10.1371/journal.pone.0065860 · DOI · Paper page
  28. Ma, 2011, The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ, Nat. Immunol., 12, 861, 10.1038/ni.2073 · DOI · Paper page
  29. Fogli, 2008, Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals, PLoS Pathog., 4, e1000101, 10.1371/journal.ppat.1000101 · DOI
  30. Gupta, 2005, Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy, Virology, 332, 491, 10.1016/j.virol.2004.12.018 · DOI
  31. Brunetta, 2009, The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia, Blood, 114, 3822, 10.1182/blood-2009-06-226332 · DOI
  32. Correia, 2011, Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells, Blood, 118, 992, 10.1182/blood-2011-02-339135 · DOI · Paper page
  33. Brunetta, 2010, Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection, AIDS, 24, 27, 10.1097/QAD.0b013e3283328d1f · doi:10.1097/qad.0b013e3283328d1f
  34. Saha, 2001, Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis, Int. Immunopharmacol., 1, 1363, 10.1016/S1567-5769(01)00068-6 · DOI
  35. Kipnis, 2004, Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration, J. Neurosci., 24, 6133, 10.1523/JNEUROSCI.0600-04.2004 · DOI · Paper page
  36. Mavilio, 2006, Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection, J. Exp. Med., 203, 2339, 10.1084/jem.20060894 · DOI · Paper page
  37. Leonard, 2005, Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation, Nat. Rev. Immunol., 5, 688, 10.1038/nri1688 · DOI · Paper page
  38. Malarkannan, 2007, Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation, J. Immunol., 179, 3752, 10.4049/jimmunol.179.6.3752 · DOI
  39. Gross, 2008, Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production, Blood, 112, 2421, 10.1182/blood-2007-11-123513 · DOI
  40. Mott, 2010, Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB, J. Cell. Biochem., 110, 1155, 10.1002/jcb.22630 · DOI · Paper page
  41. Moretta, 2002, Natural killer cells and dendritic cells: rendezvous in abused tissues, Nat. Rev. Immunol., 2, 957, 10.1038/nri956 · DOI · Paper page
  42. Cooper, 2004, NK cell and DC interactions, Trends Immunol., 25, 47, 10.1016/j.it.2003.10.012 · DOI · Paper page
  43. Degli-Esposti, 2005, Close encounters of different kinds: dendritic cells and NK cells take centre stage, Nat. Rev. Immunol., 5, 112, 10.1038/nri1549 · DOI · Paper page
  44. Costantini, 2011, Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFNgamma: role of CD18, ICAM-1, and ICAM-3, Blood, 117, 1677, 10.1182/blood-2010-06-287243 · DOI
  45. Michel, 2012, Consequences of the crosstalk between monocytes/macrophages and natural killer cells, Front. Immunol., 3, 403
  46. Hudspeth, 2013, The role of natural killer cells in autoimmune liver disease: a comprehensive review, J. Autoimmun., 46, 55, 10.1016/j.jaut.2013.07.003 · DOI
  47. Pende, 2002, Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity, Cancer Res., 62, 6178
  48. Varchetta, 2013, Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity, Cytokine, 62, 58, 10.1016/j.cyto.2013.02.018 · doi:10.1016/j.cyto.2013.02.018
  49. Johnson, 1988, cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1, Proc. Natl. Acad. Sci. USA, 85, 6072, 10.1073/pnas.85.16.6072 · doi:10.1073/pnas.85.16.6072
  50. Skålhegg, 1998, Isozymes of cyclic AMP-dependent protein kinases (PKA) in human lymphoid cell lines: levels of endogenous cAMP influence levels of PKA subunits and growth in lymphoid cell lines, J. Cell. Physiol., 177, 85, 10.1002/(SICI)1097-4652(199810)177:1<85::AID-JCP9>3.0.CO;2-A · doi:10.1002/(sici)1097-4652(199810)177:1<85::aid-jcp9>3.0.co;2-a
  51. Miller, 1999, Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor, J. Immunol., 162, 7376, 10.4049/jimmunol.162.12.7376 · DOI
  52. Lieberman, 2002, Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells, Microbes Infect., 4, 1531, 10.1016/S1286-4579(02)00036-9 · DOI
  53. Levy, 2011, Natural killer cells in human cancer: from biological functions to clinical applications, J. Biomed. Biotechnol., 2011, 676198
  54. Kai, 2010, MicroRNA assassins: factors that regulate the disappearance of miRNAs, Nat. Struct. Mol. Biol., 17, 5, 10.1038/nsmb.1762 · DOI · Paper page
  55. Volk, 2011, Versatility of MicroRNA biogenesis, PLoS ONE, 6, e19391, 10.1371/journal.pone.0019391 · DOI
  56. Ho, 1997, Overexpression of mitogen-activated protein kinase kinase kinase reversed cAMP inhibition of NF-kappaB in T cells, Eur. J. Immunol., 27, 222, 10.1002/eji.1830270133 · DOI
  57. Gerlo, 2011, Cyclic AMP: a selective modulator of NF-κB action, Cell. Mol. Life Sci., 68, 3823, 10.1007/s00018-011-0757-8 · DOI · Paper page
  58. Huang, 2012, Cutting edge: Regulatory T cells selectively attenuate, not terminate, T cell signaling by disrupting NF-κB nuclear accumulation in CD4 T cells, J. Immunol., 188, 947, 10.4049/jimmunol.1101027 · DOI
  59. Carr, 2003, In vivo administration of L-dopa or dopamine decreases the number of splenic IFN gamma-producing cells, J. Neuroimmunol., 137, 87, 10.1016/S0165-5728(03)00047-X · DOI
  60. Cosentino, 2000, HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines, Life Sci., 68, 283, 10.1016/S0024-3205(00)00937-1 · DOI
  61. Deleidi, 2013, The role of inflammation in sporadic and familial Parkinson’s disease, Cell. Mol. Life Sci., 70, 4259, 10.1007/s00018-013-1352-y · DOI · Paper page
  62. Chen, 2003, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Arch. Neurol., 60, 1059, 10.1001/archneur.60.8.1059 · DOI · Paper page
  63. Mihara, 2008, Natural killer cells of Parkinson’s disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease, Parkinsonism Relat. Disord., 14, 46, 10.1016/j.parkreldis.2007.05.013 · DOI
  64. Mosley, 2012, Inflammation and adaptive immunity in Parkinson’s disease, Cold Spring Harb. Perspect. Med., 2, a009381, 10.1101/cshperspect.a009381 · DOI · Paper page
  65. Solerte, 2000, Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer’s disease, Ann. N. Y. Acad. Sci., 917, 331, 10.1111/j.1749-6632.2000.tb05399.x · DOI
  66. Blandini, 2013, Neural and immune mechanisms in the pathogenesis of Parkinson's disease, J. Neuroimmune Pharmacol., 8, 189, 10.1007/s11481-013-9435-y · DOI · Paper page
  67. Poli, 2013, NK cells in central nervous system disorders, J. Immunol., 190, 5355, 10.4049/jimmunol.1203401 · DOI
  68. Segal, 2007, The role of natural killer cells in curbing neuroinflammation, J. Neuroimmunol., 191, 2, 10.1016/j.jneuroim.2007.09.006 · DOI

Cited by

See all 38

Metadata

Authors
Mikulak, J., Bozzo, L., Roberto, A., Pontarini, E., Tentorio, P., Hudspeth, K., Lugli, E., & Mavilio, D.
Venue
The Journal of Immunology
Published
2014-09
Volume
193
Issue
6
Pages
2792-2800
ISSN
  • 0022-1767
  • 1550-6606
Cited by
38
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor. https://app.cochat.ai/papers/10.4049/jimmunol.1401114
The paper
Mikulak, J., Bozzo, L., Roberto, A., Pontarini, E., Tentorio, P., Hudspeth, K., Lugli, E., & Mavilio, D. (2014). Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1401114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.